TScan Therapeutics Q2 EPS $(0.51) Up From $(0.63) YoY, Sales $3.15M Down From $4.06M YoY
Portfolio Pulse from Benzinga Newsdesk
TScan Therapeutics (NASDAQ:TCRX) reported Q2 losses of $(0.51) per share, a 19.05% improvement from $(0.63) per share YoY. However, sales decreased by 22.39% to $3.15 million from $4.06 million YoY.
August 10, 2023 | 11:25 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
TScan Therapeutics reported improved Q2 losses but a significant decrease in sales YoY.
While TScan Therapeutics has managed to reduce its losses per share, the significant decrease in sales could be a concern for investors. This mixed result makes the short term impact on the stock price uncertain.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100